Elevance Health stock gains on fresh analyst price target revisions

Elevance Health stock (ISIN US2855211023) is trading around USD 414 on the New York Stock Exchange as of September 18, 2026, leaving the health insurer valued at roughly USD 89.9 billion in market capitalization and reflecting modest gains in recent weeks.

Analysts adjust price targets after earnings

In the wake of Elevance Health’s latest earnings release earlier in 2026, several major analyst houses have updated their views and price targets on the stock, giving investors a fresh look at where professionals see value and risk. According to Scanx Trade on September 17, 2026, RBC Capital analyst Ben Hendrix maintained a Sector Perform rating but lowered his price target on Elevance Health to USD 424 from USD 439, signaling a slightly more cautious stance while still seeing the shares fairly valued.

The same overview from Scanx Trade reports that TD Cowen analyst Ryan Langston kept a Buy rating on Elevance Health and raised his price target to USD 465 from USD 400, while Truist Securities analyst David Macdonald also reiterated a Buy rating and increased his target to USD 475 from USD 450, highlighting confidence in the company’s earnings trajectory and cash generation.

The spread of price targets extends even higher. As noted by Scanx Trade, Wells Fargo analyst Stephen Baxter maintained an Overweight rating and lifted his price target to USD 492 from USD 391, while Barclays analyst Andrew Mok kept an Overweight stance but lowered his target to USD 457 from USD 480, providing a range of upside scenarios and underscoring that, even after revisions, most targets remain above the current share price.

Stock performance and valuation in September 2026

On the trading side, Elevance Health continues to show stable performance with moderate positive momentum. Per data for the session on September 18, 2026, Elevance Health shares trade at around USD 414.26, with the day’s high near USD 418.77 and the low around USD 411.45, indicating an intraday range of about USD 7.32 on the New York Stock Exchange and a modest advance of roughly 0.7 percent from the low to the prevailing price while still standing about 1.1 percent below the intraday high.

Trading volume for Elevance Health around September 18, 2026 is roughly 1.15 million shares compared with an average daily volume of about 1.29 million shares, suggesting that the latest analyst actions have not triggered unusually heavy trading but do coincide with a steady market bid. With the stock price near USD 414 and a price-to-earnings ratio quoted around 18.34, Elevance Health trades at a valuation in the mid-teens on forward earnings and offers a dividend yield of about 1.66 percent, a combination that many long-term investors may view as balanced between growth and income potential.

A separate overview published on September 18, 2026 by Yahoo Finance notes that Elevance Health has delivered a one-month return of 4.6 percent, placing it among so-called surging stocks on a watchlist and indicating that the recent climb in the share price is more than just a single-session move. In that same piece, Elevance Health is described as trading at USD 416.45 per share at 15.2 times forward price-to-earnings, a level broadly consistent with the valuation seen in other large-cap managed-care peers and suggesting that the stock is not at an extreme premium relative to its expected earnings.

Fundamentals: revenue scale and profitability trends

Beyond the day-to-day price action, Elevance Health’s fundamental profile remains a key anchor for the latest analyst revisions. According to the analysis cited by Yahoo Finance on September 18, 2026, the company generates a massive revenue base of USD 198.7 billion on an annualized basis, giving Elevance Health considerable bargaining power when negotiating reimbursement rates with providers and allowing it to spread fixed costs across a large membership base.

The same overview from Yahoo Finance highlights that Elevance Health’s earnings per share have grown by about 7.2 percent annually over the past five years, outpacing the peer-group average and underlining a consistent ability to convert revenue growth and cost discipline into bottom-line progress. Over the same period, the company’s return on invested capital is cited at roughly 26 percent, a level that points to robust capital allocation and efficient use of shareholder funds.

From an investor’s perspective, this combination of nearly USD 200 billion in annual revenue, mid-single-digit to high-single-digit annualized earnings growth, and a return on invested capital in the mid-20 percent range helps explain why many banks remain constructive on Elevance Health even when adjusting price targets. For example, price objectives like USD 465 from TD Cowen and USD 475 from Truist Securities, as described by Scanx Trade, suggest upside of roughly 12 to 15 percent from a share price around USD 414 if the company continues to meet or beat earnings expectations.

Risk factors and sector backdrop

Despite the supportive fundamentals and the prevalence of Buy or Overweight ratings, investors in Elevance Health must weigh several risk factors that analysts reference implicitly when setting their targets. The managed-care sector is heavily exposed to regulatory changes and public policy decisions around Medicare, Medicaid and individual marketplace plans, which can alter reimbursement structures and medical cost trends unexpectedly. When analysts like RBC Capital’s Ben Hendrix lower their price target from USD 439 to USD 424, as noted by Scanx Trade, it often reflects a reassessment of these macro variables as much as company-specific factors.

Competitive dynamics also play a role. Elevance Health operates alongside other large national insurers and regional managed-care plans, and pressure on premiums or benefits can compress margins if pricing does not fully offset rising medical costs. In the current environment, with broader equity markets recovering as described in a separate article on September 18, 2026 by Yahoo Finance, managed-care names like Elevance Health benefit from a risk-on tone, but they may face renewed scrutiny if interest rates, employment or health-care policy shift.

For shareholders, the key question over the coming quarters is whether Elevance Health can maintain its earnings-per-share growth near the 7.2 percent annual pace highlighted by Yahoo Finance while keeping return on invested capital close to the 26 percent level. If it does, the current valuation around 15 to 18 times earnings and the analyst targets between USD 424 and USD 492 indicate that the stock could remain supported by both fundamentals and institutional demand, even as sector risks persist.

Elevance Health stock price snapshot

At the close of recent trading, Elevance Health stock stands near USD 414 on the New York Stock Exchange, as of September 18, 2026, with the intraday high and low of approximately USD 418.77 and USD 411.45 framing the session’s range and a market capitalization around USD 89.9 billion reflecting its status as a major component of the United States health-care insurance landscape.

More news and analyses on Elevance Health stock